Insider Selling: Natera (NASDAQ:NTRA) Insider Sells $818,700.00 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 3,000 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $272.90, for a total transaction of $818,700.00. Following the sale, the insider directly owned 134,643 shares of the company’s stock, valued at $36,744,074.70. This represents a 2.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Solomon Moshkevich also recently made the following trade(s):

• On Monday, June 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $218.43, for a total transaction of $655,290.00.
• On Tuesday, May 26th, Solomon Moshkevich sold 1,652 shares of Natera stock. The stock was sold at an average price of $202.84, for a total transaction of $335,091.68.
• On Friday, May 1st, Solomon Moshkevich sold 3,405 shares of Natera stock. The shares were sold at an average price of $203.69, for a total transaction of $693,564.45.
• On Monday, April 27th, Solomon Moshkevich sold 2,182 shares of Natera stock. The shares were sold at an average price of $204.10, for a total transaction of $445,346.20.

Natera Price Performance

Shares of NTRA stock opened at $274.39 on Thursday. The company has a market capitalization of $39.30 billion, a P/E ratio of -168.34 and a beta of 1.51. The company’s 50-day simple moving average is $224.40 and its two-hundred day simple moving average is $218.38. Natera, Inc. has a one year low of $131.81 and a one year high of $288.04.

Institutional Trading of Natera

Hedge funds have recently bought and sold shares of the stock. Coatue Management LLC raised its position in shares of Natera by 1,446.1% in the 4th quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock worth $603,270,000 after acquiring an additional 2,463,008 shares in the last quarter. Wellington Management Group LLP grew its stake in Natera by 94.7% in the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after purchasing an additional 2,420,263 shares during the last quarter. Norges Bank bought a new position in Natera in the fourth quarter worth about $372,398,000. JPMorgan Chase & Co. raised its holdings in Natera by 10.5% in the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock worth $2,944,800,000 after purchasing an additional 1,225,420 shares in the last quarter. Finally, Franklin Resources Inc. lifted its position in shares of Natera by 37.5% during the third quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock valued at $428,987,000 after buying an additional 727,366 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on NTRA. Barclays reduced their price objective on Natera from $280.00 to $260.00 and set an “overweight” rating on the stock in a report on Wednesday, June 24th. Robert W. Baird set a $265.00 target price on Natera in a report on Friday, May 8th. Wells Fargo & Company increased their price target on Natera from $215.00 to $220.00 and gave the stock an “equal weight” rating in a research report on Friday, May 8th. Wall Street Zen lowered Natera from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Sanford C. Bernstein initiated coverage on Natera in a report on Friday, June 26th. They issued an “outperform” rating and a $310.00 price objective for the company. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $262.00.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.